Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Neoplasms | 42 | 2025 | 13594 | 2.280 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 27 | 2024 | 5434 | 2.240 |
Why?
|
Receptor Protein-Tyrosine Kinases | 8 | 2022 | 1629 | 1.110 |
Why?
|
Hematology | 4 | 2024 | 243 | 1.110 |
Why?
|
Small Cell Lung Carcinoma | 5 | 2025 | 454 | 0.950 |
Why?
|
Medical Oncology | 8 | 2024 | 2350 | 0.940 |
Why?
|
Needs Assessment | 1 | 2024 | 1143 | 0.580 |
Why?
|
Dermatitis | 1 | 2019 | 203 | 0.580 |
Why?
|
Fellowships and Scholarships | 3 | 2022 | 1134 | 0.550 |
Why?
|
Protein Kinase Inhibitors | 13 | 2023 | 5707 | 0.550 |
Why?
|
Gene Rearrangement | 3 | 2017 | 1148 | 0.540 |
Why?
|
Feedback | 2 | 2017 | 799 | 0.530 |
Why?
|
Career Choice | 1 | 2022 | 769 | 0.530 |
Why?
|
Genes, erbB-1 | 1 | 2017 | 163 | 0.520 |
Why?
|
Mutation | 18 | 2023 | 30266 | 0.430 |
Why?
|
Molecular Targeted Therapy | 7 | 2018 | 2830 | 0.380 |
Why?
|
Adenocarcinoma | 8 | 2018 | 6401 | 0.370 |
Why?
|
Immunotherapy | 2 | 2019 | 4756 | 0.360 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 2 | 2024 | 271 | 0.350 |
Why?
|
Pyrazoles | 3 | 2017 | 2029 | 0.340 |
Why?
|
Blood Glucose | 1 | 2024 | 6435 | 0.340 |
Why?
|
Protein-Tyrosine Kinases | 4 | 2017 | 2433 | 0.340 |
Why?
|
Antineoplastic Agents | 10 | 2021 | 13698 | 0.320 |
Why?
|
Pyridines | 3 | 2017 | 2895 | 0.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 11886 | 0.310 |
Why?
|
Proto-Oncogene Proteins | 4 | 2017 | 4528 | 0.270 |
Why?
|
Exons | 3 | 2023 | 2395 | 0.260 |
Why?
|
Cancer Vaccines | 1 | 2013 | 1043 | 0.260 |
Why?
|
Students, Medical | 1 | 2016 | 1964 | 0.210 |
Why?
|
Humans | 58 | 2025 | 768970 | 0.210 |
Why?
|
Mutagenesis, Insertional | 2 | 2021 | 662 | 0.190 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2019 | 5342 | 0.190 |
Why?
|
Carbazoles | 2 | 2022 | 230 | 0.180 |
Why?
|
ras-GRF1 | 1 | 2020 | 26 | 0.180 |
Why?
|
Quinazolinones | 1 | 2021 | 219 | 0.170 |
Why?
|
Ethylnitrosourea | 1 | 2019 | 50 | 0.170 |
Why?
|
Internship and Residency | 2 | 2017 | 5956 | 0.170 |
Why?
|
Palliative Care | 2 | 2021 | 3644 | 0.170 |
Why?
|
Alkylating Agents | 1 | 2019 | 132 | 0.160 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2019 | 99 | 0.160 |
Why?
|
Female | 30 | 2025 | 397515 | 0.150 |
Why?
|
Brain Neoplasms | 3 | 2021 | 9213 | 0.150 |
Why?
|
Disease-Free Survival | 4 | 2017 | 6856 | 0.150 |
Why?
|
Survival Rate | 4 | 2021 | 12873 | 0.150 |
Why?
|
Education, Distance | 1 | 2021 | 260 | 0.140 |
Why?
|
Acrylamides | 1 | 2019 | 261 | 0.140 |
Why?
|
Central Nervous System | 1 | 2025 | 1346 | 0.140 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2019 | 147 | 0.140 |
Why?
|
Organophosphorus Compounds | 1 | 2018 | 211 | 0.140 |
Why?
|
Treatment Outcome | 11 | 2025 | 65480 | 0.140 |
Why?
|
Piperazines | 2 | 2025 | 2553 | 0.130 |
Why?
|
DNA Mutational Analysis | 4 | 2018 | 4124 | 0.130 |
Why?
|
Middle Aged | 19 | 2025 | 223737 | 0.130 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2018 | 423 | 0.130 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2017 | 239 | 0.120 |
Why?
|
Education, Medical, Graduate | 3 | 2022 | 2422 | 0.120 |
Why?
|
Mutagenesis | 1 | 2019 | 1229 | 0.120 |
Why?
|
Retrospective Studies | 10 | 2024 | 81903 | 0.120 |
Why?
|
Genetic Testing | 2 | 2019 | 3591 | 0.120 |
Why?
|
Aged | 17 | 2025 | 171786 | 0.120 |
Why?
|
Male | 23 | 2025 | 365203 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2015 | 567 | 0.120 |
Why?
|
Gene Amplification | 2 | 2017 | 1099 | 0.120 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2020 | 1616 | 0.120 |
Why?
|
Bethanechol | 1 | 2014 | 12 | 0.120 |
Why?
|
Immunoconjugates | 1 | 2022 | 976 | 0.110 |
Why?
|
Hepatitis B | 1 | 2020 | 711 | 0.110 |
Why?
|
Malacoplakia | 1 | 2014 | 15 | 0.110 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2016 | 450 | 0.110 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2017 | 2525 | 0.110 |
Why?
|
Piperidines | 2 | 2022 | 1667 | 0.110 |
Why?
|
Aniline Compounds | 1 | 2019 | 1095 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2018 | 620 | 0.110 |
Why?
|
Hemoglobins | 1 | 2019 | 1531 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 906 | 0.100 |
Why?
|
Neoplasm Staging | 4 | 2021 | 11262 | 0.100 |
Why?
|
Specimen Handling | 1 | 2017 | 708 | 0.100 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4862 | 0.100 |
Why?
|
Aged, 80 and over | 8 | 2025 | 59739 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1748 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1120 | 0.090 |
Why?
|
Germ-Line Mutation | 1 | 2019 | 1887 | 0.090 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2015 | 342 | 0.090 |
Why?
|
Prognosis | 5 | 2024 | 30046 | 0.090 |
Why?
|
HIV | 1 | 2018 | 1597 | 0.090 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2020 | 2848 | 0.090 |
Why?
|
Ascorbic Acid | 1 | 2014 | 658 | 0.090 |
Why?
|
Alternative Splicing | 1 | 2015 | 1105 | 0.090 |
Why?
|
Genetic Association Studies | 1 | 2019 | 2748 | 0.080 |
Why?
|
Phthalazines | 2 | 2025 | 397 | 0.080 |
Why?
|
Hepatitis C | 1 | 2020 | 1595 | 0.080 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 2862 | 0.080 |
Why?
|
Neoplasms | 2 | 2019 | 22389 | 0.080 |
Why?
|
Faculty, Medical | 1 | 2017 | 1226 | 0.080 |
Why?
|
Fatal Outcome | 3 | 2020 | 1836 | 0.080 |
Why?
|
Adult | 11 | 2025 | 223851 | 0.080 |
Why?
|
Genomics | 3 | 2019 | 5928 | 0.080 |
Why?
|
Renal Insufficiency | 1 | 2014 | 812 | 0.070 |
Why?
|
Curriculum | 2 | 2017 | 3782 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6547 | 0.070 |
Why?
|
Receptor, erbB-2 | 1 | 2017 | 2606 | 0.070 |
Why?
|
Immunohistochemistry | 2 | 2018 | 11116 | 0.070 |
Why?
|
Survival Analysis | 1 | 2019 | 10115 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2960 | 0.070 |
Why?
|
Pneumonia | 1 | 2018 | 2164 | 0.070 |
Why?
|
Pyrimidines | 1 | 2018 | 3048 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 18068 | 0.060 |
Why?
|
Antigens, Neoplasm | 1 | 2013 | 2001 | 0.060 |
Why?
|
Education, Medical | 1 | 2016 | 1742 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5375 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4064 | 0.060 |
Why?
|
Renal Dialysis | 1 | 2014 | 1789 | 0.060 |
Why?
|
Time Factors | 3 | 2021 | 40261 | 0.060 |
Why?
|
Cells, Cultured | 1 | 2019 | 19023 | 0.050 |
Why?
|
Patient Selection | 1 | 2015 | 4265 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2020 | 7885 | 0.050 |
Why?
|
Clinical Trials as Topic | 2 | 2022 | 8055 | 0.050 |
Why?
|
Membrane Glycoproteins | 1 | 2013 | 3713 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2016 | 15471 | 0.050 |
Why?
|
Obesity | 1 | 2024 | 13091 | 0.050 |
Why?
|
Quality of Life | 1 | 2024 | 13510 | 0.050 |
Why?
|
Pandemics | 1 | 2022 | 8749 | 0.050 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 3608 | 0.050 |
Why?
|
Caregivers | 1 | 2013 | 2308 | 0.050 |
Why?
|
Cohort Studies | 2 | 2021 | 41808 | 0.040 |
Why?
|
Mice | 4 | 2021 | 82072 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2019 | 3621 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2024 | 12253 | 0.040 |
Why?
|
Smoking | 1 | 2017 | 9094 | 0.040 |
Why?
|
Videoconferencing | 1 | 2021 | 209 | 0.040 |
Why?
|
Chromosomal Instability | 1 | 2019 | 176 | 0.040 |
Why?
|
Camptothecin | 1 | 2022 | 600 | 0.040 |
Why?
|
Republic of Korea | 1 | 2020 | 592 | 0.040 |
Why?
|
Kidney | 1 | 2014 | 7058 | 0.040 |
Why?
|
Phenotype | 1 | 2015 | 16731 | 0.040 |
Why?
|
Dexamethasone | 1 | 2024 | 1965 | 0.030 |
Why?
|
Amino Acids | 1 | 2023 | 1716 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2013 | 9264 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2024 | 21188 | 0.030 |
Why?
|
Videotape Recording | 1 | 2017 | 335 | 0.030 |
Why?
|
Cell Line, Tumor | 3 | 2018 | 17173 | 0.030 |
Why?
|
Pleural Neoplasms | 1 | 2021 | 612 | 0.030 |
Why?
|
Animals | 4 | 2021 | 169335 | 0.030 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2021 | 735 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10765 | 0.030 |
Why?
|
ras Proteins | 1 | 2020 | 1058 | 0.030 |
Why?
|
Education | 1 | 2017 | 533 | 0.030 |
Why?
|
Autopsy | 1 | 2018 | 1013 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2018 | 498 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2025 | 9442 | 0.030 |
Why?
|
Muscarinic Agonists | 1 | 2014 | 91 | 0.030 |
Why?
|
Oncogenes | 1 | 2019 | 1236 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2011 | 5443 | 0.030 |
Why?
|
Etoposide | 1 | 2015 | 639 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1340 | 0.030 |
Why?
|
MAP Kinase Signaling System | 1 | 2020 | 1495 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2021 | 2916 | 0.030 |
Why?
|
Tumor Burden | 1 | 2018 | 1913 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2021 | 3554 | 0.020 |
Why?
|
Workflow | 1 | 2017 | 859 | 0.020 |
Why?
|
Carboplatin | 1 | 2015 | 799 | 0.020 |
Why?
|
Fluoroquinolones | 1 | 2014 | 309 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2014 | 684 | 0.020 |
Why?
|
HIV Infections | 1 | 2018 | 17591 | 0.020 |
Why?
|
Genomic Instability | 1 | 2015 | 715 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2022 | 2909 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2021 | 18354 | 0.020 |
Why?
|
Smad4 Protein | 1 | 2011 | 193 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2021 | 4926 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2021 | 13427 | 0.020 |
Why?
|
Teaching | 1 | 2017 | 1171 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2167 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1769 | 0.020 |
Why?
|
Program Evaluation | 1 | 2017 | 2508 | 0.020 |
Why?
|
Organ Size | 1 | 2014 | 2268 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2021 | 2565 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 20776 | 0.020 |
Why?
|
Cell Line | 1 | 2021 | 15604 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3671 | 0.020 |
Why?
|
Urinary Tract Infections | 1 | 2014 | 805 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2017 | 2884 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3562 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2019 | 3628 | 0.020 |
Why?
|
Prospective Studies | 2 | 2021 | 54962 | 0.020 |
Why?
|
Antioxidants | 1 | 2014 | 1673 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5323 | 0.020 |
Why?
|
Cell Survival | 1 | 2015 | 5793 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2021 | 4363 | 0.010 |
Why?
|
Phosphorylation | 1 | 2015 | 8317 | 0.010 |
Why?
|
Genetic Variation | 1 | 2019 | 6611 | 0.010 |
Why?
|
Radiography | 1 | 2015 | 6991 | 0.010 |
Why?
|
Communication | 1 | 2017 | 3908 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2017 | 4056 | 0.010 |
Why?
|
Biopsy | 1 | 2014 | 6805 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 6673 | 0.010 |
Why?
|
Genotype | 1 | 2015 | 13048 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7460 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 13021 | 0.010 |
Why?
|
Disease Progression | 1 | 2015 | 13674 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2014 | 4423 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39394 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2014 | 7478 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2011 | 22296 | 0.010 |
Why?
|
Adolescent | 1 | 2019 | 89244 | 0.010 |
Why?
|
Concepts
(204)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(83)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_